[go: up one dir, main page]

MX373669B - Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso. - Google Patents

Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.

Info

Publication number
MX373669B
MX373669B MX2016003855A MX2016003855A MX373669B MX 373669 B MX373669 B MX 373669B MX 2016003855 A MX2016003855 A MX 2016003855A MX 2016003855 A MX2016003855 A MX 2016003855A MX 373669 B MX373669 B MX 373669B
Authority
MX
Mexico
Prior art keywords
divergent
composition
vaccine
porcine circovirus
circovirus type
Prior art date
Application number
MX2016003855A
Other languages
English (en)
Other versions
MX2016003855A (es
Inventor
Gregory Paul Nitzel
David Ewell Slade
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of MX2016003855A publication Critical patent/MX2016003855A/es
Publication of MX373669B publication Critical patent/MX373669B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10044—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición de vacuna para proteger a los cerdos frente al PCV2, incluyendo una cepa de circovirus porcino tipo 2b (PCV2b) divergente altamente virulenta, incluyendo la composición un polipéptido de ORF2 de PCV2b divergente, en donde el polipéptido de ORF2 comprende leucina (L) en la posición 89, treonina (T) en la posición 90 y asparagina (N) en la posición 134, de acuerdo con la numeración de SEQ ID NO: 1 en el presente documento.
MX2016003855A 2013-09-25 2014-09-24 Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso. MX373669B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361882289P 2013-09-25 2013-09-25
PCT/US2014/057190 WO2015048115A1 (en) 2013-09-25 2014-09-24 Pcv2b divergent vaccine composition and methods of use

Publications (2)

Publication Number Publication Date
MX2016003855A MX2016003855A (es) 2016-08-04
MX373669B true MX373669B (es) 2020-04-02

Family

ID=51688446

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003855A MX373669B (es) 2013-09-25 2014-09-24 Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.

Country Status (12)

Country Link
US (1) US9987348B2 (es)
EP (2) EP3049106A1 (es)
JP (2) JP6821429B2 (es)
KR (2) KR102319843B1 (es)
CN (1) CN105579060B (es)
BR (1) BR112016006192A2 (es)
CA (1) CA2925281C (es)
HK (1) HK1225645A1 (es)
MX (1) MX373669B (es)
PH (1) PH12016500473B1 (es)
RU (1) RU2662685C2 (es)
WO (1) WO2015048115A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2994162T3 (pl) 2013-05-08 2021-10-18 Pharmgate Biologics Inc. Szczepionka przeciwko pcv2 i mykoplazmie
MX373669B (es) * 2013-09-25 2020-04-02 Zoetis Services Llc Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.
EA201800494A1 (ru) * 2016-03-07 2019-07-31 Вирджиния Тех Интеллектуал Пропертис, Инк. Вакцины против химерного цирковируса свиней типа 2 (pcv2)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN106754980A (zh) * 2016-12-29 2017-05-31 福州大学 Pcv2型衣壳蛋白基因、表达菌株及可溶性表达方法
MX385295B (es) * 2017-10-17 2025-03-18 Intervet Int Bv Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
BR112020025211A2 (pt) * 2018-06-11 2021-03-09 Ceva Sante Animale Vacinação contra circovírus suíno
CN110606873B (zh) * 2019-09-09 2021-05-04 武汉科前生物股份有限公司 猪圆环病毒2d型与3型Cap蛋白二联亚单位疫苗及其制备方法与应用
KR102769557B1 (ko) * 2021-11-19 2025-02-20 주식회사 이노백 신규한 재조합 돼지 써코바이러스 2형 단백질 및 이의 용도
CN115960259B (zh) * 2022-10-07 2023-11-24 浙江大学 一种模块化组装双组分纳米颗粒制备方法及其应用
WO2024096648A1 (ko) * 2022-11-03 2024-05-10 주식회사 옵티팜 신규한 재조합 pcv2d 항원 및 이의 용도
CN117100851A (zh) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 一种佐剂、疫苗组合物及其制备方法和应用
US20250332243A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Methods of manufacturing porcine endogenous retrovirus (perv) free animal health vaccines
US20250332242A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Porcine endogenous retrovirus (perv)-free porcine circovirus type 2d-based vaccines and methods of use

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262533A (en) 1939-12-09 1941-11-11 William D Hedge Water-cooled grate
FR964808A (es) 1941-03-20 1950-08-25
FR2422956A1 (fr) 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
FR2518755B1 (fr) 1981-12-23 1986-04-11 Pasteur Institut Sonde contenant un acide nucleique modifie et reconnaissable par des anticorps specifiques et utilisation de cette sonde pour detecter et caracteriser une sequence d'adn homologue
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5550289A (en) 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
US5106733A (en) 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
SU1538305A1 (ru) 1987-07-21 1994-12-15 Всесоюзный государственный научно-контрольный институт ветеринарных препаратов Госагропрома СССР Ассоциированная вакцина против лептоспироза и парвовирусной инфекции свиней
US5238662A (en) 1987-07-31 1993-08-24 Chevron Research Company Processes for recovering precious metals
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
AU638970B2 (en) 1989-01-23 1993-07-15 Auspharm International Limited Vaccine composition
US5811103A (en) 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ES2112274T5 (es) 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US5147966A (en) 1990-07-31 1992-09-15 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polyimide molding powder, coating, adhesive and matrix resin
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
WO1992005255A1 (en) 1990-09-13 1992-04-02 Commonwealth Scientific And Industrial Research Organisation Ovine cytokine genes
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
CA2094515C (en) 1990-11-01 1998-09-01 Theodore T. Kramer Bacterial attenuation method and vaccine
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
ES2026827A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
US5580557A (en) 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US6033904A (en) 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
AU4662393A (en) 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
EP0683816B1 (en) 1993-02-08 2000-11-02 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
EP0698245A1 (en) 1993-05-14 1996-02-28 Mds Health Group Limited Electronic worksheet system for microbiology testing and reporting
JPH09500013A (ja) 1993-06-01 1997-01-07 ライフ・テクノロジーズ・インコーポレイテッド カチオン性脂質による遺伝子免疫
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
JP3911010B2 (ja) 1994-04-29 2007-05-09 イムノ・アクテイエンゲゼルシヤフト 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス
NZ285324A (en) 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
DK53595A (da) 1994-05-13 1995-11-14 Iberica Cyanamid Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
US6043232A (en) 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
WO1996040931A1 (en) 1995-06-07 1996-12-19 Aesculaap B.V. Neutralizing conformational epitopes of chicken anemia virus
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5795872A (en) 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
ATE199022T1 (de) 1996-10-09 2001-02-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
WO1998040499A1 (en) 1997-03-10 1998-09-17 Heather Lynn Davis Gene delivery to mucosal epithelium for immunization or therapeutic purposes
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2769322B1 (fr) 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6165493A (en) 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
JP2001523481A (ja) 1997-11-26 2001-11-27 アイオワ ステイト ユニヴァーシティ リサーチ ファウンデーション インコーポレイテッド 組換えｈｙｏ肺炎マイコプラズマワクチン
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
CA2313806A1 (en) 1997-12-11 1999-06-17 University Of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
US6287856B1 (en) 1998-03-13 2001-09-11 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
AU1131200A (en) 1998-10-23 2000-05-15 Heska Corporation Cationic lipid-mediated enhancement of nucleic acid immunization of cats
NZ513289A (en) 1998-12-22 2003-04-29 Pfizer Prod Inc Infectious cDNA clone of north american procine reproductive and respiratory syndrome (PRRS) virus and uses thereof
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6179461B1 (en) 1999-09-03 2001-01-30 Davis-Standard Corporation Extruder screw
US6139179A (en) 1999-09-03 2000-10-31 Davis-Standard Corporation Extruder screw having multi-channeled barrier section
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
JP2004503234A (ja) 2000-06-15 2004-02-05 パーデュー・リサーチ・ファウンデーション ブタの先天性振せん用ワクチン
DE10044648A1 (de) 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
CZ304525B6 (cs) 2001-03-27 2014-06-18 University Of Saskatchewan Způsob kultivace circoviru
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
SI1546357T1 (sl) 2002-06-28 2013-10-30 Iowa State University Research Foundation, Inc. Imunogeni polipeptidi mycoplasma hyopneumoniae
US7312065B2 (en) 2003-07-25 2007-12-25 Boehringer Ingelheim Vetmedica, Inc. Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods of use thereof
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
KR20070096019A (ko) 2005-01-13 2007-10-01 베링거잉겔하임베트메디카게엠베하 향상된 ｐｒｒｓ 백신
WO2006113435A2 (en) 2005-04-13 2006-10-26 Merial Limited Method for porcine circovirus production and assays for monitoring production
BRPI0615862A2 (pt) * 2005-09-09 2011-05-31 Intervet Int Bv vacina contra pcv-2, e, método para a manufatura de uma vacina
DK1968630T5 (en) * 2005-12-29 2018-08-13 Boehringer Ingelheim Vetmedica Inc MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS.
SG170792A1 (en) 2005-12-29 2011-05-30 Boehringer Ingelheim Vetmed Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
WO2008076915A2 (en) * 2006-12-15 2008-06-26 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with pcv2 antigen
US20090017064A1 (en) 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
WO2009085912A1 (en) 2007-12-21 2009-07-09 Wyeth Methods and compositions for immunizing pigs against porcine circovirus
EA201100862A1 (ru) 2008-11-28 2012-01-30 Сева Санте Анималь Новый изолят свиного цирковируса типа 2b и его применения
EP2547770B1 (en) * 2010-03-16 2019-11-27 Virginia Tech Intellectual Properties, Inc. Live attenuated chimeric porcine circovirus vaccine
CN102296089B (zh) * 2011-04-20 2013-09-11 中国兽医药品监察所 高效制备猪圆环病毒2型空衣壳粒子的方法
RU2628313C2 (ru) * 2011-05-27 2017-08-15 Синовет (Бейджинг) Байотекнолоджи Ко.,Лтд Комбинированные вакцины для профилактики вирусных инфекций свиней
CN103122352B (zh) * 2012-09-27 2015-02-11 华中农业大学 一种猪圆环病毒2型重组杆状病毒及制备方法和应用
WO2015026912A1 (en) 2013-08-23 2015-02-26 Boehringer Ingelheim Vetmedica, Inc. Porcine circovirus type 2 (pcv2) subunit vaccine
MX373669B (es) * 2013-09-25 2020-04-02 Zoetis Services Llc Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.

Also Published As

Publication number Publication date
US20160220658A1 (en) 2016-08-04
JP2019206541A (ja) 2019-12-05
CA2925281A1 (en) 2015-04-02
JP2016531854A (ja) 2016-10-13
MX2016003855A (es) 2016-08-04
HK1225645A1 (zh) 2017-09-15
WO2015048115A1 (en) 2015-04-02
US9987348B2 (en) 2018-06-05
PH12016500473B1 (en) 2020-02-28
JP6821429B2 (ja) 2021-01-27
KR102319843B1 (ko) 2021-10-29
CN105579060B (zh) 2021-03-16
KR20160046879A (ko) 2016-04-29
RU2016110430A (ru) 2017-10-30
CA2925281C (en) 2022-05-03
EP4091629A1 (en) 2022-11-23
KR20180041245A (ko) 2018-04-23
CN105579060A (zh) 2016-05-11
BR112016006192A2 (pt) 2017-09-26
EP3049106A1 (en) 2016-08-03
PH12016500473A1 (en) 2016-05-16
RU2662685C2 (ru) 2018-07-26

Similar Documents

Publication Publication Date Title
MX373669B (es) Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.
MX2019009443A (es) Metodos para tratar la influenza.
UY36180A (es) Difluorometil-indanil-carboxamidas nicotínicas
BR112018068078A2 (pt) vacinas de circovírus suíno tipo 2 (pcv2) quimérico
MX358099B (es) Anticuerpos que neutralizan el virus de inmunodeficiencia humano y metodos de uso de ellos.
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
MX2021001053A (es) Vacunas contra virus de la influenza y sus usos.
MX2014003308A (es) Vacunas para el virus de la influenza y usos de las mismas.
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
MX381488B (es) Indoles para su uso en la infección por el virus de la gripe.
CL2015001724A1 (es) Compuestos derivados de péptidos, agonistas de oxitocina; composicion farmaceutica; y su uso para en el tratamiento del autismo, estres, ansiedad, depresion, esquizofrenia,entre otros.
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
AR102658A1 (es) Composición para el tratamiento de telas
MX2017016401A (es) Composiciones inmunogenas.
BR112018010679A2 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CL2016000300A1 (es) Métodos terapéuticos
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
MX363464B (es) Vacunas contra influenza h5.
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration